Skip to content

Multimodal treatment of perianal fistulas in Crohn's Disesase: seton versus anti-TNF versus advancement plasty

Multimodal treatment of perianal fistulas in Crohn's Disesase: seton versus anti-TNF versus advancement plasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON22680
Enrollment
126
Registered
2013-08-23
Start date
2013-08-29
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perianal fistulas, Crohn's disease perianale fistels, ziekte van Crohn

Interventions

Group 1: chronic seton drainage Group 2: anti-TNF Group 3: Advancement plasty All patients start at T=0 with the insertion of a seton(s) in day care setting. This will be done under antibiotics pro

Sponsors

Academic Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - ≥ 18 years - Written informed consent - High tract (intersphincteric, transsphincteric, suprasphincteric) perianal fistula located in the upper two-thirds of the external sphincter - Fistula with one internal opening (based on MRI imaging). The number of external fistulas does not have to be taken into account - Both new fistulas or recurrent active fistula (defined as any producing fistula)

Exclusion criteria

Exclusion criteria: - Proctitis (defined as any active mucosal inflammation or ulcer > 5mm in the rectum) - Anorectal stenosis (defined as the impossibility to introduce a proctoscope) - Submucosal fistulas & low intersphincteric fistulas (lower one-third of external sphincter) - Rectovaginal fistula - Multiple internal openings - Seton in situ for more than 3 months - Use of Anti-TNF medication during last 3 months - Previous Anti-TNF medication without any effect on perianal fistulas - Previously demonstrated allergy for anti-TNF medication. If this allergy only concerns the chimeric monoclonal mouse-antibody infliximab, the patient could be randomised for adalumimab - Patients with a stoma - Immunocompromised patients (i.e. haematological malignancies, HIV/AIDS, bone marrow transplantation, splenectomy, genetic disorders such as severe combined immunodeficiency, chemotherapy, dialysis, solid organ transplant and long term immunosuppressant use such as corticosteroids in patients with rheumatoid arthritis) - Life expectancy < 2 years - The inability of reading/understanding and filling in the questionnaires - Dementia or altered mental status that would prohibit the understanding and giving of informed consent

Design outcomes

Primary

MeasureTime frame
The primary objective of this study is to analyse the number of patients that need a re-intervention due to fistula-related complications (abscesses, recurrent or new tract formation).

Secondary

MeasureTime frame
The secondary outcomes parameters will be the number of patients with closed fistulas (based on MRI findings) after 18 months, Perianal Disease Activity Index (PDAI score) and number of necessary antibiotics courses during fistula treatment, quality of life (EQ-5D and IBDQ), and costs (KEA and BIA).

Contacts

Public ContactM.E. Stellingwerf

AMC

m.e.stellingwerf@amc.nl+31(0)205662860

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)